

21-gene panel may let some breast cancer patients skip chemo

The Oncotype DX test appears accurate for use in determining whether women with early-stage breast cancer can forgo chemotherapy, according to results scheduled for presentation at the European Breast Cancer Conference. Women with scores of 11 or lower on the test's 100-point scale were treated with anti-hormonal therapy only, and nearly all were alive and cancer-free at 55 months follow-up. Women with scores higher than 11 or other risk factors were randomly assigned to one of two chemotherapy arms. Ninety-four percent with moderate-risk cancer and 84% with high-risk cancer were alive and free of cancer at five years follow-up. [HealthDay News](#) (3/11)

--